The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | SUCCESSOR-2: efficacy of mezigdomide in high-risk and standard-risk myeloma
Meletios Dimopoulos, MD, Kapodistrian University of Athens School of Medicine, Athens, Greece, discusses findings from the Phase III SUCCESSOR-2 trial (NCT05552976), evaluating mezigdomide plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed/refractory multiple myeloma. Dr Dimopoulos highlights the progression-free survival (PFS) benefit observed in patients with high-risk cytogenetics, noting that the treatment benefit was consistent across high-risk and standard-risk subgroups, although longer follow-up is needed. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
